Price T Rowe Associates Inc Bei Gene, Ltd. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,020,127 shares of BGNE stock, worth $231 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,020,127

Previous 2,713,418 62.4%

Holding current value

$231 Million

Previous $739 Million 66.56%

% of portfolio

0.03%

Previous 0.09%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	N/A	-1,693,291 Reduced 62.4%	1,020,127 $247 Million
Q1 2025 May 14, 2025	SELL	$175.1 - $226.71 $39.2 Million - $50.7 Million	-223,752 Reduced 7.62%	2,713,418 $739 Million
Q4 2024 Feb 14, 2025	BUY	$174.72 - $246.04 $41.4 Million - $58.3 Million	237,082 Added 8.78%	2,937,170 $543 Million
Q3 2024 Nov 14, 2024	BUY	$143.93 - $224.51 $61.5 Million - $95.9 Million	427,266 Added 18.8%	2,700,088 $606 Million
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $32 Million - $43 Million	246,728 Added 12.18%	2,272,822 $324 Million
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $16.7 Million - $21.4 Million	117,905 Added 6.18%	2,026,094 $317 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $25.2 Million - $32 Million	158,624 Added 9.07%	1,908,189 $344 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $47.6 Million - $59.6 Million	264,691 Added 17.83%	1,749,565 $315 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $126 Million - $189 Million	709,017 Added 91.39%	1,484,874 $265 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $67.8 Million - $86.4 Million	314,764 Added 68.26%	775,857 $167 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $1.72 Million - $3.14 Million	13,676 Added 3.06%	461,093 $101 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $1.94 Million - $2.98 Million	-14,727 Reduced 3.19%	447,417 $60.3 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $7.79 Million - $13.9 Million	-64,352 Reduced 12.22%	462,144 $74.8 Million
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $4.58 Million - $8.43 Million	-31,264 Reduced 5.61%	526,496 $99.3 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $3.25 Million - $5.1 Million	-13,093 Reduced 2.29%	557,760 $151 Million
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $2.81 Million - $4.53 Million	-11,240 Reduced 1.93%	570,853 $207 Million
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $43.3 Million - $54.3 Million	-147,837 Reduced 20.25%	582,093 $200 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $28 Million - $41.1 Million	-107,448 Reduced 12.83%	729,930 $254 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $185 Million - $265 Million	837,378 New	837,378 $216 Million

Others Institutions Holding BGNE

# of Institutions

269

Shares Held

32.2M

Call Options Held

113K

Put Options Held

106K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Bei Gene, Ltd. Transaction History